ID   TSP1_HUMAN              Reviewed;        1170 AA.
AC   P07996; A8K6H4; B4E3J7; B9EGH6; Q15667; Q59E99;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2006, sequence version 2.
DT   18-JUN-2025, entry version 267.
DE   RecName: Full=Thrombospondin-1;
DE   AltName: Full=Glycoprotein G {ECO:0000303|PubMed:6777381};
DE   Flags: Precursor;
GN   Name=THBS1 {ECO:0000312|HGNC:HGNC:11785}; Synonyms=TSP, TSP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Endothelial cell;
RX   PubMed=2430973; DOI=10.1083/jcb.103.5.1635;
RA   Lawler J., Hynes R.O.;
RT   "The structure of human thrombospondin, an adhesive glycoprotein with
RT   multiple calcium-binding sites and homologies with several different
RT   proteins.";
RL   J. Cell Biol. 103:1635-1648(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-523.
RX   PubMed=2918029; DOI=10.1083/jcb.108.2.729;
RA   Hennessy S.W., Frazier B.A., Kim D.D., Deckwerth T.L., Baumgartel D.M.,
RA   Rotwein P., Frazier W.A.;
RT   "Complete thrombospondin mRNA sequence includes potential regulatory sites
RT   in the 3' untranslated region.";
RL   J. Cell Biol. 108:729-736(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ALA-523.
RC   TISSUE=Placenta, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-700.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-397 (ISOFORM 1).
RX   PubMed=3030396; DOI=10.1021/bi00374a014;
RA   Kobayashi S., Eden-Mccutchan F., Framson P., Bornstein P.;
RT   "Partial amino acid sequence of human thrombospondin as determined by
RT   analysis of cDNA clones: homology to malarial circumsporozoite proteins.";
RL   Biochemistry 25:8418-8425(1986).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-374 (ISOFORM 1).
RX   PubMed=3461443; DOI=10.1073/pnas.83.15.5449;
RA   Dixit V.M., Hennessy S.W., Grant G.A., Rotwein P., Frazier W.A.;
RT   "Characterization of a cDNA encoding the heparin and collagen binding
RT   domains of human thrombospondin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5449-5453(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-166.
RX   PubMed=2544587; DOI=10.1016/s0021-9258(18)60452-1;
RA   Laherty C.D., Gierman T.M., Dixit V.M.;
RT   "Characterization of the promoter region of the human thrombospondin gene.
RT   DNA sequences within the first intron increase transcription.";
RL   J. Biol. Chem. 264:11222-11227(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1028-1170 (ISOFORM 1).
RA   la Fleur M., Jobin C., Gauthier J., Kreis C.G.;
RT   "Expression of thrombospondin in chronic inflammation: neutrophils from
RT   synovial fluids synthesize a novel 3.9 kb TSP mRNA.";
RL   Submitted (DEC-1992) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=101549; DOI=10.1016/s0021-9258(17)34336-3;
RA   Lawler J.W., Slayter H.S., Coligan J.E.;
RT   "Isolation and characterization of a high molecular weight glycoprotein
RT   from human blood platelets.";
RL   J. Biol. Chem. 253:8609-8616(1978).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=6777381; DOI=10.1016/s0021-9258(19)70174-4;
RA   Phillips D.R., Jennings L.K., Prasanna H.R.;
RT   "Ca2+-mediated association of glycoprotein G (thrombin-sensitive protein,
RT   thrombospondin) with human platelets.";
RL   J. Biol. Chem. 255:11629-11632(1980).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=6341993; DOI=10.1073/pnas.80.4.998;
RA   Jaffe E.A., Ruggiero J.T., Leung L.K., Doyle M.J., McKeown-Longo P.J.,
RA   Mosher D.F.;
RT   "Cultured human fibroblasts synthesize and secrete thrombospondin and
RT   incorporate it into extracellular matrix.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:998-1002(1983).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH FIBRONECTIN AND FIBRINOGEN.
RX   PubMed=6489349; DOI=10.1111/j.1432-1033.1984.tb08534.x;
RA   Lahav J., Lawler J., Gimbrone M.A.;
RT   "Thrombospondin interactions with fibronectin and fibrinogen. Mutual
RT   inhibition in binding.";
RL   Eur. J. Biochem. 145:151-156(1984).
RN   [15]
RP   INTERACTION WITH TYPE V COLLAGEN AND LAMININ.
RX   PubMed=6693501; DOI=10.1083/jcb.98.2.646;
RA   Mumby S.M., Raugi G.J., Bornstein P.;
RT   "Interactions of thrombospondin with extracellular matrix proteins:
RT   selective binding to type V collagen.";
RL   J. Cell Biol. 98:646-652(1984).
RN   [16]
RP   INTERACTION WITH INTEGRIN RECEPTOR.
RX   PubMed=2478219;
RA   Lawler J., Hynes R.O.;
RT   "An integrin receptor on normal and thrombasthenic platelets that binds
RT   thrombospondin.";
RL   Blood 74:2022-2027(1989).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH CD36.
RX   PubMed=1371676; DOI=10.1016/0006-291x(92)91860-s;
RA   Asch A.S., Silbiger S., Heimer E., Nachman R.L.;
RT   "Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding.";
RL   Biochem. Biophys. Res. Commun. 182:1208-1217(1992).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH CD47.
RX   PubMed=8550562; DOI=10.1074/jbc.271.1.21;
RA   Gao A.G., Lindberg F.P., Finn M.B., Blystone S.D., Brown E.J.,
RA   Frazier W.A.;
RT   "Integrin-associated protein is a receptor for the C-terminal domain of
RT   thrombospondin.";
RL   J. Biol. Chem. 271:21-24(1996).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH CD36.
RX   PubMed=10613822; DOI=10.1038/71517;
RA   Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L.,
RA   Bouck N.;
RT   "Signals leading to apoptosis-dependent inhibition of neovascularization by
RT   thrombospondin-1.";
RL   Nat. Med. 6:41-48(2000).
RN   [20]
RP   GLYCOSYLATION AT TRP-385; SER-394; TRP-438; TRP-441; THR-450; TRP-498 AND
RP   THR-507.
RC   TISSUE=Platelet;
RX   PubMed=11067851; DOI=10.1074/jbc.m008073200;
RA   Hofsteenge J., Huwiler K.G., Macek B., Hess D., Lawler J., Mosher D.F.,
RA   Peter-Katalinic J.;
RT   "C-mannosylation and O-fucosylation of the thrombospondin type 1 module.";
RL   J. Biol. Chem. 276:6485-6498(2001).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH HRG.
RX   PubMed=11134179; DOI=10.1172/jci9061;
RA   Simantov R., Febbraio M., Crombie R., Asch A.S., Nachman R.L.,
RA   Silverstein R.L.;
RT   "Histidine-rich glycoprotein inhibits the antiangiogenic effect of
RT   thrombospondin-1.";
RL   J. Clin. Invest. 107:45-52(2001).
RN   [22]
RP   DISULFIDE BONDS IN THROMBOSPONDIN DOMAIN.
RX   PubMed=12450399; DOI=10.1021/bi026463u;
RA   Huwiler K.G., Vestling M.M., Annis D.S., Mosher D.F.;
RT   "Biophysical characterization, including disulfide bond assignments, of the
RT   anti-angiogenic type 1 domains of human thrombospondin-1.";
RL   Biochemistry 41:14329-14339(2002).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, INDUCTION BY PROSTAGLANDIN E2, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=14568985; DOI=10.1084/jem.20030705;
RA   Doyen V., Rubio M., Braun D., Nakajima T., Abe J., Saito H., Delespesse G.,
RA   Sarfati M.;
RT   "Thrombospondin 1 is an autocrine negative regulator of human dendritic
RT   cell activation.";
RL   J. Exp. Med. 198:1277-1283(2003).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-248 AND ASN-1067.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [25]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1067.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T., Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by glycoprotein
RT   capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [26]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-248.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.m500324-mcp200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [27]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-926 AND
RP   1019-ASP--ASP-1021.
RX   PubMed=18285447; DOI=10.1242/jcs.021006;
RA   Adams J.C., Bentley A.A., Kvansakul M., Hatherley D., Hohenester E.;
RT   "Extracellular matrix retention of thrombospondin 1 is controlled by its
RT   conserved C-terminal region.";
RL   J. Cell Sci. 121:784-795(2008).
RN   [28]
RP   INTERACTION WITH FN1.
RX   PubMed=18042364; DOI=10.1016/j.matbio.2007.10.003;
RA   Kuznetsova S.A., Mahoney D.J., Martin-Manso G., Ali T., Nentwich H.A.,
RA   Sipes J.M., Zeng B., Vogel T., Day A.J., Roberts D.D.;
RT   "TSG-6 binds via its CUB_C domain to the cell-binding domain of fibronectin
RT   and increases fibronectin matrix assembly.";
RL   Matrix Biol. 27:201-210(2008).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH CD47.
RX   PubMed=19004835; DOI=10.1074/jbc.m804860200;
RA   Isenberg J.S., Annis D.S., Pendrak M.L., Ptaszynska M., Frazier W.A.,
RA   Mosher D.F., Roberts D.D.;
RT   "Differential interactions of thrombospondin-1, -2, and -4 with CD47 and
RT   effects on cGMP signaling and ischemic injury responses.";
RL   J. Biol. Chem. 284:1116-1125(2009).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1067.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH SIRPA.
RX   PubMed=24511121; DOI=10.1681/asn.2013040433;
RA   Yao M., Rogers N.M., Csanyi G., Rodriguez A.I., Ross M.A., St Croix C.,
RA   Knupp H., Novelli E.M., Thomson A.W., Pagano P.J., Isenberg J.S.;
RT   "Thrombospondin-1 activation of signal-regulatory protein-alpha stimulates
RT   reactive oxygen species production and promotes renal ischemia reperfusion
RT   injury.";
RL   J. Am. Soc. Nephrol. 25:1171-1186(2014).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   INDUCTION.
RX   PubMed=27742621; DOI=10.1093/cvr/cvw218;
RA   Rogers N.M., Sharifi-Sanjani M., Yao M., Ghimire K., Bienes-Martinez R.,
RA   Mutchler S.M., Knupp H.E., Baust J., Novelli E.M., Ross M., St Croix C.,
RA   Kutten J.C., Czajka C.A., Sembrat J.C., Rojas M., Labrousse-Arias D.,
RA   Bachman T.N., Vanderpool R.R., Zuckerbraun B.S., Champion H.C., Mora A.L.,
RA   Straub A.C., Bilonick R.A., Calzada M.J., Isenberg J.S.;
RT   "TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and
RT   contributes to pulmonary arterial vasculopathy and dysfunction.";
RL   Cardiovasc. Res. 113:15-29(2017).
RN   [35]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=29042481; DOI=10.1126/scisignal.aaj1784;
RA   Meijles D.N., Sahoo S., Al Ghouleh I., Amaral J.H., Bienes-Martinez R.,
RA   Knupp H.E., Attaran S., Sembrat J.C., Nouraie S.M., Rojas M.M.,
RA   Novelli E.M., Gladwin M.T., Isenberg J.S., Cifuentes-Pagano E.,
RA   Pagano P.J.;
RT   "The matricellular protein TSP1 promotes human and mouse endothelial cell
RT   senescence through CD47 and Nox1.";
RL   Sci. Signal. 10:0-0(2017).
RN   [36]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=32679764; DOI=10.3390/cells9071695;
RA   Ghimire K., Li Y., Chiba T., Julovi S.M., Li J., Ross M.A., Straub A.C.,
RA   O'Connell P.J., Rueegg C., Pagano P.J., Isenberg J.S., Rogers N.M.;
RT   "CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and
RT   Glucose Homeostasis.";
RL   Cells 9:0-0(2020).
RN   [37]
RP   GLYCOSYLATION AT SER-553.
RX   PubMed=38237698; DOI=10.1016/j.mcpro.2024.100717;
RA   Houlahan C.B., Kong Y., Johnston B., Cielesh M., Chau T.H., Fenwick J.,
RA   Coleman P.R., Hao H., Haltiwanger R.S., Thaysen-Andersen M., Passam F.H.,
RA   Larance M.;
RT   "Analysis of the Healthy Platelet Proteome Identifies a New Form of Domain-
RT   Specific O-Fucosylation.";
RL   Mol. Cell. Proteomics 23:100717-100717(2024).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 434-546, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT THR-450 AND THR-507.
RX   PubMed=12391027; DOI=10.1083/jcb.200206062;
RA   Tan K., Duquette M., Liu J.-H., Dong Y., Zhang R., Joachimiak A.,
RA   Lawler J., Wang J.-H.;
RT   "Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and
RT   its biological implication.";
RL   J. Cell Biol. 159:373-382(2002).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 834-1170 IN COMPLEX WITH CALCIUM
RP   IONS, DISULFIDE BONDS, MUTAGENESIS OF ASN-1067, GLYCOSYLATION AT ASN-1067,
RP   CELL ATTACHMENT SITE, AND FUNCTION.
RX   PubMed=15014436; DOI=10.1038/sj.emboj.7600166;
RA   Kvansakul M., Adams J.C., Hohenester E.;
RT   "Structure of a thrombospondin C-terminal fragment reveals a novel calcium
RT   core in the type 3 repeats.";
RL   EMBO J. 23:1223-1233(2004).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 19-233 IN COMPLEX WITH SYNTHETIC
RP   PENTAMERIC HEPARIN, AND DISULFIDE BOND.
RX   PubMed=16407063; DOI=10.1016/j.str.2005.09.017;
RA   Tan K., Duquette M., Liu J.-H., Zhang R., Joachimiak A., Wang J.-H.,
RA   Lawler J.;
RT   "The structures of the thrombospondin-1 N-terminal domain and its complex
RT   with a synthetic pentameric heparin.";
RL   Structure 14:33-42(2006).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 19-257 IN COMPLEXES WITH HEPARIN,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND GLYCOSYLATION AT ASN-248.
RX   PubMed=18065761; DOI=10.1074/jbc.m705203200;
RA   Tan K., Duquette M., Liu J.-H., Shanmugasundaram K., Joachimiak A.,
RA   Gallagher J.T., Rigby A.C., Wang J.-H., Lawler J.;
RT   "Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1
RT   N-terminal domain.";
RL   J. Biol. Chem. 283:3932-3941(2008).
CC   -!- FUNCTION: Adhesive glycoprotein that mediates cell-to-cell and cell-to-
CC       matrix interactions (PubMed:15014436, PubMed:18285447, PubMed:2430973,
CC       PubMed:6489349). Multifunctional, involved in inflammation,
CC       angiogenesis, wound healing, reactive oxygen species (ROS) signaling,
CC       nitrous oxide (NO) signaling, apoptosis, senescence, aging, cellular
CC       self-renewal, stemness, and cardiovascular and metabolic homeostasis
CC       (PubMed:10613822, PubMed:11134179, PubMed:1371676, PubMed:14568985,
CC       PubMed:24511121, PubMed:29042481, PubMed:32679764). Negatively
CC       modulates dendritic cell activation and cytokine release, as part of an
CC       autocrine feedback loop, contributing to the resolution of inflammation
CC       and immune homeostasis (PubMed:14568985). Ligand for receptor CD47
CC       (PubMed:19004835, PubMed:8550562). Modulates nitrous oxide (NO)
CC       signaling via CD47, hence playing a role as a pressor agent, supporting
CC       blood pressure (By similarity). Plays a role in endothelial cell
CC       senescence, acting via CD47, by increasing the abundance and activation
CC       of NADPH oxidase NOX1, and so generating excess ROS (PubMed:29042481).
CC       Inhibits stem cell self-renewal, acting via CD47 signaling, probably by
CC       regulation of the stem cell transcription factors POU5F1/OCT4, SOX2,
CC       MYC/c-Myc and KLF4 (By similarity). Negatively modulates wound healing,
CC       acting via CD47 (By similarity). Ligand for receptor CD36
CC       (PubMed:10613822, PubMed:11134179, PubMed:1371676). Involved in
CC       inducing apoptosis in podocytes in response to elevated free fatty
CC       acids, acting via CD36 (By similarity). Plays a role in suppressing
CC       angiogenesis, acting, depending on context, via CD36 or CD47
CC       (PubMed:10613822, PubMed:11134179, PubMed:1371676, PubMed:32679764).
CC       Promotes cellular senescence in a TP53-CDKN1A-RB1 signaling-dependent
CC       manner (PubMed:29042481). Ligand for immunoglobulin-like cell surface
CC       receptor SIRPA (PubMed:24511121). Involved in ROS signaling in non-
CC       phagocytic cells, stimulating NADPH oxidase-derived ROS production,
CC       acting via interaction with SIRPA (PubMed:24511121). Plays a role in
CC       metabolic dysfunction in diet-induced obesity, perhaps acting by
CC       exacerbating adipose inflammatory activity; its effects may be
CC       mediated, at least in part, through enhanced adipocyte proliferation
CC       (By similarity). Plays a role in ER stress response, via its
CC       interaction with the activating transcription factor 6 alpha (ATF6)
CC       which produces adaptive ER stress response factors (By similarity). May
CC       be involved in age-related conditions, including metabolic
CC       dysregulation, during normal aging (PubMed:29042481, PubMed:32679764).
CC       {ECO:0000250|UniProtKB:P35441, ECO:0000269|PubMed:10613822,
CC       ECO:0000269|PubMed:11134179, ECO:0000269|PubMed:1371676,
CC       ECO:0000269|PubMed:14568985, ECO:0000269|PubMed:15014436,
CC       ECO:0000269|PubMed:18285447, ECO:0000269|PubMed:19004835,
CC       ECO:0000269|PubMed:2430973, ECO:0000269|PubMed:24511121,
CC       ECO:0000269|PubMed:29042481, ECO:0000269|PubMed:32679764,
CC       ECO:0000269|PubMed:6489349, ECO:0000269|PubMed:8550562}.
CC   -!- SUBUNIT: Homotrimer; disulfide-linked (PubMed:101549, PubMed:18285447).
CC       Can bind to fibrinogen, fibronectin, laminin, type V collagen and
CC       integrins alpha-V/beta-1, alpha-V/beta-3 and alpha-IIb/beta-3
CC       (PubMed:2478219, PubMed:6489349, PubMed:6693501). Binds heparin
CC       (PubMed:101549, PubMed:16407063, PubMed:18065761). Interacts (via the
CC       C-terminal domain) with CD47 (PubMed:19004835, PubMed:8550562).
CC       Interacts (via the TSP type I repeats) with CD36; the interaction
CC       conveys an antiangiogenic effect (PubMed:10613822, PubMed:1371676).
CC       Interacts (via the TSP type I repeats) with HRG; the interaction blocks
CC       the antiangiogenic effect of THBS1 with CD36 (PubMed:11134179).
CC       Interacts with ATF6 (via lumenal domain) (By similarity). Interacts
CC       with FN1; this interaction is enhanced by TNFAIP6, which may act as a
CC       bridging molecule between FN1 and THBS1 (PubMed:18042364). Interacts
CC       with SIRPA; the interaction stimulates phosphorylation of SIRPA
CC       (PubMed:24511121). {ECO:0000250|UniProtKB:P35441,
CC       ECO:0000269|PubMed:101549, ECO:0000269|PubMed:10613822,
CC       ECO:0000269|PubMed:11134179, ECO:0000269|PubMed:1371676,
CC       ECO:0000269|PubMed:16407063, ECO:0000269|PubMed:18042364,
CC       ECO:0000269|PubMed:18065761, ECO:0000269|PubMed:18285447,
CC       ECO:0000269|PubMed:19004835, ECO:0000269|PubMed:24511121,
CC       ECO:0000269|PubMed:2478219, ECO:0000269|PubMed:6489349,
CC       ECO:0000269|PubMed:6693501, ECO:0000269|PubMed:8550562}.
CC   -!- INTERACTION:
CC       P07996; P02751: FN1; NbExp=2; IntAct=EBI-2530274, EBI-1220319;
CC       P07996; Q15113: PCOLCE; NbExp=3; IntAct=EBI-2530274, EBI-8869614;
CC       P07996; P01137: TGFB1; NbExp=2; IntAct=EBI-2530274, EBI-779636;
CC       PRO_0000035842; P16671: CD36; NbExp=2; IntAct=EBI-13915509, EBI-2808214;
CC       PRO_0000035842; Q92743: HTRA1; NbExp=2; IntAct=EBI-13915509, EBI-352256;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:101549,
CC       ECO:0000269|PubMed:14568985, ECO:0000269|PubMed:6777381}. Cell surface
CC       {ECO:0000269|PubMed:6777381}. Secreted, extracellular space,
CC       extracellular matrix {ECO:0000269|PubMed:18285447,
CC       ECO:0000269|PubMed:6341993}. Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P35441}. Sarcoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P35441}. Note=Secreted by thrombin-activated
CC       platelets and binds to the cell surface in the presence of
CC       extracellular Ca(2+) (PubMed:101549, PubMed:6777381). Incorporated into
CC       the extracellular matrix (ECM) of fibroblasts (PubMed:6341993). The C-
CC       terminal region in trimeric form is required for retention in the ECM
CC       (PubMed:18285447). Also detected in the endoplasmic reticulum and
CC       sarcoplasmic reticulum where it plays a role in the ER stress response
CC       (By similarity). {ECO:0000250|UniProtKB:P35441,
CC       ECO:0000269|PubMed:6341993, ECO:0000269|PubMed:6777381}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07996-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07996-2; Sequence=VSP_055757;
CC   -!- TISSUE SPECIFICITY: Expressed by platelets (at protein level)
CC       (PubMed:101549). Expressed by monocyte-derived immature and mature
CC       dendritic cells (at protein level) (PubMed:14568985).
CC       {ECO:0000269|PubMed:101549, ECO:0000269|PubMed:14568985}.
CC   -!- INDUCTION: Expression is induced by PGE2, S.aureus and
CC       lipopolysaccharide (PubMed:14568985). Induced in arteries and lung
CC       parenchyma following injury or stress (PubMed:27742621). Expression in
CC       vasculature, including arteries, increases in normal aging
CC       (PubMed:29042481, PubMed:32679764). {ECO:0000269|PubMed:14568985,
CC       ECO:0000269|PubMed:27742621, ECO:0000269|PubMed:29042481,
CC       ECO:0000269|PubMed:32679764}.
CC   -!- SIMILARITY: Belongs to the thrombospondin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93149.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/42548/THBS1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04665; CAA28370.1; -; mRNA.
DR   EMBL; X14787; CAA32889.1; -; mRNA.
DR   EMBL; AK291639; BAF84328.1; -; mRNA.
DR   EMBL; AK304754; BAG65509.1; -; mRNA.
DR   EMBL; AB209912; BAD93149.1; ALT_INIT; mRNA.
DR   EMBL; AC037198; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC136469; AAI36470.1; -; mRNA.
DR   EMBL; BC136470; AAI36471.1; -; mRNA.
DR   EMBL; M25631; AAA36741.1; -; mRNA.
DR   EMBL; M14326; AAA61237.1; ALT_SEQ; mRNA.
DR   EMBL; J04835; AAA61178.1; -; Genomic_DNA.
DR   EMBL; M99425; AAB59366.1; -; mRNA.
DR   CCDS; CCDS32194.1; -. [P07996-1]
DR   PIR; A26155; TSHUP1.
DR   RefSeq; NP_003237.2; NM_003246.3. [P07996-1]
DR   RefSeq; XP_047288936.1; XM_047432980.1. [P07996-1]
DR   RefSeq; XP_054234660.1; XM_054378685.1. [P07996-1]
DR   PDB; 1LSL; X-ray; 1.90 A; A=434-546.
DR   PDB; 1UX6; X-ray; 1.90 A; A=834-1170.
DR   PDB; 1Z78; X-ray; 1.80 A; A=19-233.
DR   PDB; 1ZA4; X-ray; 1.90 A; A=19-257.
DR   PDB; 2ERF; X-ray; 1.45 A; A=25-233.
DR   PDB; 2ES3; X-ray; 1.85 A; A/B=25-233.
DR   PDB; 2OUH; X-ray; 2.40 A; A/B=19-257.
DR   PDB; 2OUJ; X-ray; 1.90 A; A=19-257.
DR   PDB; 3R6B; X-ray; 2.40 A; A=434-547.
DR   PDB; 5FOE; X-ray; 1.98 A; A/B=378-429.
DR   PDB; 7YYK; X-ray; 2.60 A; A=378-547.
DR   PDBsum; 1LSL; -.
DR   PDBsum; 1UX6; -.
DR   PDBsum; 1Z78; -.
DR   PDBsum; 1ZA4; -.
DR   PDBsum; 2ERF; -.
DR   PDBsum; 2ES3; -.
DR   PDBsum; 2OUH; -.
DR   PDBsum; 2OUJ; -.
DR   PDBsum; 3R6B; -.
DR   PDBsum; 5FOE; -.
DR   PDBsum; 7YYK; -.
DR   AlphaFoldDB; P07996; -.
DR   SMR; P07996; -.
DR   BioGRID; 112915; 125.
DR   ComplexPortal; CPX-1785; Thrombospondin 1 complex.
DR   CORUM; P07996; -.
DR   DIP; DIP-1037N; -.
DR   FunCoup; P07996; 1163.
DR   IntAct; P07996; 61.
DR   MINT; P07996; -.
DR   STRING; 9606.ENSP00000260356; -.
DR   BindingDB; P07996; -.
DR   ChEMBL; CHEMBL4630810; -.
DR   DrugBank; DB05434; ABT-510.
DR   GlyConnect; 594; 88 N-Linked glycans (6 sites), 1 O-Fuc glycan (1 site), 1 O-Linked glycan (3 sites).
DR   GlyCosmos; P07996; 15 sites, 94 glycans.
DR   GlyGen; P07996; 23 sites, 207 N-linked glycans (6 sites), 7 O-linked glycans (12 sites).
DR   iPTMnet; P07996; -.
DR   MetOSite; P07996; -.
DR   PhosphoSitePlus; P07996; -.
DR   SwissPalm; P07996; -.
DR   BioMuta; THBS1; -.
DR   DMDM; 117949802; -.
DR   OGP; P07996; -.
DR   CPTAC; non-CPTAC-1162; -.
DR   jPOST; P07996; -.
DR   MassIVE; P07996; -.
DR   PaxDb; 9606-ENSP00000260356; -.
DR   PeptideAtlas; P07996; -.
DR   ProteomicsDB; 52058; -. [P07996-1]
DR   Pumba; P07996; -.
DR   ABCD; P07996; 6 sequenced antibodies.
DR   Antibodypedia; 9950; 715 antibodies from 38 providers.
DR   DNASU; 7057; -.
DR   Ensembl; ENST00000260356.6; ENSP00000260356.5; ENSG00000137801.11. [P07996-1]
DR   GeneID; 7057; -.
DR   KEGG; hsa:7057; -.
DR   MANE-Select; ENST00000260356.6; ENSP00000260356.5; NM_003246.4; NP_003237.2.
DR   UCSC; uc001zkh.4; human. [P07996-1]
DR   AGR; HGNC:11785; -.
DR   CTD; 7057; -.
DR   DisGeNET; 7057; -.
DR   GeneCards; THBS1; -.
DR   HGNC; HGNC:11785; THBS1.
DR   HPA; ENSG00000137801; Low tissue specificity.
DR   MalaCards; THBS1; -.
DR   MIM; 188060; gene.
DR   neXtProt; NX_P07996; -.
DR   OpenTargets; ENSG00000137801; -.
DR   PharmGKB; PA36497; -.
DR   VEuPathDB; HostDB:ENSG00000137801; -.
DR   eggNOG; ENOG502QRK8; Eukaryota.
DR   GeneTree; ENSGT00940000155832; -.
DR   HOGENOM; CLU_009257_0_0_1; -.
DR   InParanoid; P07996; -.
DR   OMA; ITQTYWD; -.
DR   OrthoDB; 14563at2759; -.
DR   PAN-GO; P07996; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; P07996; -.
DR   TreeFam; TF324917; -.
DR   PathwayCommons; P07996; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-5083635; Defective B3GALTL causes PpS.
DR   Reactome; R-HSA-5173214; O-glycosylation of TSR domain-containing proteins.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   SignaLink; P07996; -.
DR   SIGNOR; P07996; -.
DR   BioGRID-ORCS; 7057; 10 hits in 1076 CRISPR screens.
DR   ChiTaRS; THBS1; human.
DR   EvolutionaryTrace; P07996; -.
DR   GeneWiki; Thrombospondin_1; -.
DR   GenomeRNAi; 7057; -.
DR   Pharos; P07996; Tchem.
DR   PRO; PR:P07996; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P07996; protein.
DR   Bgee; ENSG00000137801; Expressed in stromal cell of endometrium and 190 other cell types or tissues.
DR   ExpressionAtlas; P07996; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:BHF-UCL.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; NAS:BHF-UCL.
DR   GO; GO:0070052; F:collagen V binding; IDA:BHF-UCL.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; HDA:BHF-UCL.
DR   GO; GO:0070051; F:fibrinogen binding; IDA:UniProtKB.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:BHF-UCL.
DR   GO; GO:0001968; F:fibronectin binding; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IMP:BHF-UCL.
DR   GO; GO:0043236; F:laminin binding; IDA:BHF-UCL.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IDA:BHF-UCL.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0043394; F:proteoglycan binding; TAS:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048266; P:behavioral response to pain; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; NAS:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IDA:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; NAS:BHF-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0002544; P:chronic inflammatory response; IEP:BHF-UCL.
DR   GO; GO:0043652; P:engulfment of apoptotic cell; IDA:BHF-UCL.
DR   GO; GO:0006955; P:immune response; IEP:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IDA:CACAO.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0002581; P:negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II; IDA:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:1903588; P:negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IDA:MGI.
DR   GO; GO:0010754; P:negative regulation of cGMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0002605; P:negative regulation of dendritic cell antigen processing and presentation; IDA:BHF-UCL.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; IDA:MGI.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IDA:MGI.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0040037; P:negative regulation of fibroblast growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; TAS:BHF-UCL.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; IDA:UniProtKB.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IDA:UniProtKB.
DR   GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0010751; P:negative regulation of nitric oxide mediated signal transduction; IDA:MGI.
DR   GO; GO:0010757; P:negative regulation of plasminogen activation; IDA:BHF-UCL.
DR   GO; GO:1903671; P:negative regulation of sprouting angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0038060; P:nitric oxide-cGMP-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IDA:BHF-UCL.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:1902043; P:positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; IDA:BHF-UCL.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; IDA:BHF-UCL.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IMP:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032914; P:positive regulation of transforming growth factor beta1 production; ISS:BHF-UCL.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0009749; P:response to glucose; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; NAS:BHF-UCL.
DR   GO; GO:0032026; P:response to magnesium ion; IDA:BHF-UCL.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; TAS:BHF-UCL.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0006986; P:response to unfolded protein; IEA:UniProtKB-KW.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:UniProtKB.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:BHF-UCL.
DR   CDD; cd00054; EGF_CA; 1.
DR   FunFam; 2.20.100.10:FF:000007; Thrombospondin 1; 2.
DR   FunFam; 2.60.120.200:FF:000009; Thrombospondin 1; 1.
DR   FunFam; 2.10.25.10:FF:000070; Thrombospondin 2; 1.
DR   FunFam; 4.10.1080.10:FF:000003; Thrombospondin 2; 1.
DR   FunFam; 2.10.25.10:FF:000025; Thrombospondin 3; 1.
DR   FunFam; 2.10.25.10:FF:000027; Thrombospondin 3; 1.
DR   FunFam; 4.10.1080.10:FF:000001; Thrombospondin 3; 1.
DR   FunFam; 2.20.100.10:FF:000115; Thrombospondin type-1 domain-containing protein 1; 1.
DR   FunFam; 2.60.120.200:FF:000041; thrombospondin-1; 1.
DR   Gene3D; 2.60.120.200; -; 2.
DR   Gene3D; 6.20.200.20; -; 1.
DR   Gene3D; 2.10.25.10; Laminin; 3.
DR   Gene3D; 2.20.100.10; Thrombospondin type-1 (TSP1) repeat; 3.
DR   Gene3D; 4.10.1080.10; TSP type-3 repeat; 2.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003367; Thrombospondin_3-like_rpt.
DR   InterPro; IPR017897; Thrombospondin_3_rpt.
DR   InterPro; IPR008859; Thrombospondin_C.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   InterPro; IPR028974; TSP_type-3_rpt.
DR   InterPro; IPR048287; TSPN-like_N.
DR   InterPro; IPR001007; VWF_dom.
DR   PANTHER; PTHR10199; THROMBOSPONDIN; 1.
DR   PANTHER; PTHR10199:SF78; THROMBOSPONDIN-1; 1.
DR   Pfam; PF00090; TSP_1; 3.
DR   Pfam; PF02412; TSP_3; 7.
DR   Pfam; PF05735; TSP_C; 1.
DR   Pfam; PF00093; VWC; 1.
DR   PRINTS; PR01705; TSP1REPEAT.
DR   SMART; SM00181; EGF; 3.
DR   SMART; SM00179; EGF_CA; 2.
DR   SMART; SM00209; TSP1; 3.
DR   SMART; SM00210; TSPN; 1.
DR   SMART; SM00214; VWC; 1.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   SUPFAM; SSF57196; EGF/Laminin; 1.
DR   SUPFAM; SSF57603; FnI-like domain; 1.
DR   SUPFAM; SSF103647; TSP type-3 repeat; 3.
DR   SUPFAM; SSF82895; TSP-1 type 1 repeat; 3.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 2.
DR   PROSITE; PS50092; TSP1; 3.
DR   PROSITE; PS51234; TSP3; 8.
DR   PROSITE; PS51236; TSP_CTER; 1.
DR   PROSITE; PS01208; VWFC_1; 1.
DR   PROSITE; PS50184; VWFC_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Apoptosis; Calcium;
KW   Cell adhesion; Disulfide bond; EGF-like domain; Endoplasmic reticulum;
KW   Extracellular matrix; Glycoprotein; Heparin-binding; Inflammatory response;
KW   Proteomics identification; Reference proteome; Repeat;
KW   Sarcoplasmic reticulum; Secreted; Signal; Unfolded protein response.
FT   SIGNAL          1..18
FT   CHAIN           19..1170
FT                   /note="Thrombospondin-1"
FT                   /id="PRO_0000035842"
FT   DOMAIN          65..270
FT                   /note="Laminin G-like"
FT   DOMAIN          316..373
FT                   /note="VWFC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00220"
FT   DOMAIN          379..429
FT                   /note="TSP type-1 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          435..490
FT                   /note="TSP type-1 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          492..547
FT                   /note="TSP type-1 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          547..587
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          646..690
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REPEAT          691..726
FT                   /note="TSP type-3 1"
FT   REPEAT          727..762
FT                   /note="TSP type-3 2"
FT   REPEAT          763..785
FT                   /note="TSP type-3 3"
FT   REPEAT          786..821
FT                   /note="TSP type-3 4"
FT   REPEAT          822..844
FT                   /note="TSP type-3 5"
FT   REPEAT          845..882
FT                   /note="TSP type-3 6"
FT   REPEAT          883..918
FT                   /note="TSP type-3 7"
FT   REPEAT          919..954
FT                   /note="TSP type-3 8"
FT   DOMAIN          958..1170
FT                   /note="TSP C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00635"
FT   REGION          47..95
FT                   /note="Heparin-binding"
FT   REGION          531..1152
FT                   /note="Involved in retention in extracellular matrix (ECM);
FT                   involved in trimer formation"
FT                   /evidence="ECO:0000269|PubMed:18285447"
FT   REGION          839..934
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           926..928
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000305"
FT   COMPBIAS        840..854
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        883..894
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        917..934
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        248
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305|PubMed:16263699,
FT                   ECO:0000305|PubMed:16335952, ECO:0000305|PubMed:18065761"
FT   CARBOHYD        360
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        385
FT                   /note="C-linked (Man) tryptophan"
FT                   /evidence="ECO:0000269|PubMed:11067851"
FT                   /id="CAR_000205"
FT   CARBOHYD        394
FT                   /note="O-linked (Fuc...) serine"
FT                   /evidence="ECO:0000269|PubMed:11067851"
FT                   /id="CAR_000206"
FT   CARBOHYD        438
FT                   /note="C-linked (Man) tryptophan"
FT                   /evidence="ECO:0000269|PubMed:11067851"
FT                   /id="CAR_000207"
FT   CARBOHYD        441
FT                   /note="C-linked (Man) tryptophan"
FT                   /evidence="ECO:0000269|PubMed:11067851"
FT                   /id="CAR_000208"
FT   CARBOHYD        450
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:11067851,
FT                   ECO:0000269|PubMed:12391027"
FT                   /id="CAR_000209"
FT   CARBOHYD        498
FT                   /note="C-linked (Man) tryptophan"
FT                   /evidence="ECO:0000269|PubMed:11067851"
FT                   /id="CAR_000210"
FT   CARBOHYD        507
FT                   /note="O-linked (Fuc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:11067851,
FT                   ECO:0000269|PubMed:12391027"
FT                   /id="CAR_000211"
FT   CARBOHYD        553
FT                   /note="O-linked (Xyl) serine"
FT                   /evidence="ECO:0000269|PubMed:38237698"
FT   CARBOHYD        708
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1067
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15014436,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:16740002,
FT                   ECO:0000269|PubMed:19159218"
FT   DISULFID        171..232
FT                   /evidence="ECO:0000269|PubMed:16407063,
FT                   ECO:0000269|PubMed:18065761, ECO:0007744|PDB:1Z78,
FT                   ECO:0007744|PDB:2ERF, ECO:0007744|PDB:2ES3,
FT                   ECO:0007744|PDB:2OUH, ECO:0007744|PDB:2OUJ"
FT   DISULFID        270
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305"
FT   DISULFID        274
FT                   /note="Interchain"
FT                   /evidence="ECO:0000305"
FT   DISULFID        391..423
FT   DISULFID        395..428
FT   DISULFID        406..413
FT   DISULFID        447..484
FT                   /evidence="ECO:0000269|PubMed:12391027,
FT                   ECO:0007744|PDB:1LSL"
FT   DISULFID        451..489
FT                   /evidence="ECO:0000269|PubMed:12391027,
FT                   ECO:0007744|PDB:1LSL"
FT   DISULFID        462..474
FT                   /evidence="ECO:0000269|PubMed:12391027,
FT                   ECO:0007744|PDB:1LSL"
FT   DISULFID        504..541
FT                   /evidence="ECO:0000269|PubMed:12391027,
FT                   ECO:0007744|PDB:1LSL"
FT   DISULFID        508..546
FT                   /evidence="ECO:0000269|PubMed:12391027,
FT                   ECO:0007744|PDB:1LSL"
FT   DISULFID        519..531
FT                   /evidence="ECO:0000269|PubMed:12391027,
FT                   ECO:0007744|PDB:1LSL"
FT   DISULFID        551..562
FT                   /evidence="ECO:0000250"
FT   DISULFID        556..572
FT                   /evidence="ECO:0000250"
FT   DISULFID        575..586
FT                   /evidence="ECO:0000250"
FT   DISULFID        592..608
FT                   /evidence="ECO:0000250"
FT   DISULFID        599..617
FT                   /evidence="ECO:0000250"
FT   DISULFID        620..644
FT                   /evidence="ECO:0000250"
FT   DISULFID        650..663
FT                   /evidence="ECO:0000250"
FT   DISULFID        657..676
FT                   /evidence="ECO:0000250"
FT   DISULFID        678..689
FT                   /evidence="ECO:0000250"
FT   DISULFID        705..713
FT                   /evidence="ECO:0000250"
FT   DISULFID        718..738
FT                   /evidence="ECO:0000250"
FT   DISULFID        754..774
FT                   /evidence="ECO:0000250"
FT   DISULFID        777..797
FT                   /evidence="ECO:0000250"
FT   DISULFID        813..833
FT                   /evidence="ECO:0000250"
FT   DISULFID        836..856
FT                   /evidence="ECO:0000269|PubMed:15014436,
FT                   ECO:0007744|PDB:1UX6"
FT   DISULFID        874..894
FT                   /evidence="ECO:0000269|PubMed:15014436,
FT                   ECO:0007744|PDB:1UX6"
FT   DISULFID        910..930
FT                   /evidence="ECO:0000269|PubMed:15014436,
FT                   ECO:0007744|PDB:1UX6"
FT   DISULFID        946..1167
FT                   /evidence="ECO:0000269|PubMed:15014436,
FT                   ECO:0007744|PDB:1UX6"
FT   VAR_SEQ         17..101
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055757"
FT   VARIANT         24
FT                   /note="S -> A (in dbSNP:rs41515347)"
FT                   /id="VAR_052657"
FT   VARIANT         523
FT                   /note="T -> A (in dbSNP:rs2292305)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:2918029"
FT                   /id="VAR_028938"
FT   VARIANT         700
FT                   /note="N -> S (in dbSNP:rs2228262)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_028939"
FT   MUTAGEN         926
FT                   /note="R->V: Reduces attachment to cells and retention in
FT                   extracellular matrix (ECM); retention in ECM partially
FT                   dependent on beta-1 integrin."
FT                   /evidence="ECO:0000269|PubMed:18285447"
FT   MUTAGEN         1019..1021
FT                   /note="DDD->AAA: Reduces attachment to cells and retention
FT                   in extracellular matrix."
FT                   /evidence="ECO:0000269|PubMed:18285447"
FT   MUTAGEN         1067
FT                   /note="N->K: Loss of N-glycosylation site."
FT                   /evidence="ECO:0000269|PubMed:15014436"
FT   CONFLICT        4
FT                   /note="A -> S (in Ref. 3; BAG65509)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        84
FT                   /note="A -> T (in Ref. 1; CAA28370 and 9; AAA61178)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        431
FT                   /note="R -> I (in Ref. 3; BAG65509)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        451
FT                   /note="C -> R (in Ref. 3; BAG65509)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        546
FT                   /note="C -> Y (in Ref. 3; BAF84328)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        812
FT                   /note="N -> D (in Ref. 3; BAG65509)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1008
FT                   /note="F -> S (in Ref. 3; BAF84328)"
FT                   /evidence="ECO:0000305"
FT   STRAND          30..32
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   HELIX           33..37
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   TURN            38..41
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          44..49
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          58..62
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   HELIX           64..66
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   HELIX           72..85
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          87..96
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          101..109
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          115..122
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   TURN            123..126
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          127..134
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          137..145
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          150..161
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          164..169
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   TURN            170..172
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          173..178
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   HELIX           191..194
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          195..200
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   TURN            203..205
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   STRAND          210..218
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   HELIX           223..228
FT                   /evidence="ECO:0007829|PDB:2ERF"
FT   TURN            229..231
FT                   /evidence="ECO:0007829|PDB:2OUH"
FT   STRAND          394..403
FT                   /evidence="ECO:0007829|PDB:5FOE"
FT   TURN            408..410
FT                   /evidence="ECO:0007829|PDB:5FOE"
FT   STRAND          417..424
FT                   /evidence="ECO:0007829|PDB:5FOE"
FT   STRAND          450..459
FT                   /evidence="ECO:0007829|PDB:1LSL"
FT   STRAND          469..471
FT                   /evidence="ECO:0007829|PDB:7YYK"
FT   STRAND          478..485
FT                   /evidence="ECO:0007829|PDB:1LSL"
FT   STRAND          507..509
FT                   /evidence="ECO:0007829|PDB:1LSL"
FT   STRAND          511..516
FT                   /evidence="ECO:0007829|PDB:1LSL"
FT   STRAND          535..541
FT                   /evidence="ECO:0007829|PDB:1LSL"
FT   TURN            838..840
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          849..852
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   TURN            854..856
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          865..867
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   HELIX           869..871
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          888..890
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   HELIX           892..894
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          901..903
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   HELIX           905..907
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   TURN            909..912
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          924..926
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   HELIX           928..930
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          937..939
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   TURN            941..943
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          961..965
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          986..988
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          995..1014
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1022..1031
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1034..1043
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1051..1053
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1059..1067
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   HELIX           1074..1081
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1082..1084
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   TURN            1087..1089
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1090..1095
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1107..1115
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   TURN            1116..1119
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1120..1127
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1130..1134
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1146..1154
FT                   /evidence="ECO:0007829|PDB:1UX6"
FT   STRAND          1156..1167
FT                   /evidence="ECO:0007829|PDB:1UX6"
SQ   SEQUENCE   1170 AA;  129383 MW;  74749B2418E0943B CRC64;
     MGLAWGLGVL FLMHVCGTNR IPESGGDNSV FDIFELTGAA RKGSGRRLVK GPDPSSPAFR
     IEDANLIPPV PDDKFQDLVD AVRAEKGFLL LASLRQMKKT RGTLLALERK DHSGQVFSVV
     SNGKAGTLDL SLTVQGKQHV VSVEEALLAT GQWKSITLFV QEDRAQLYID CEKMENAELD
     VPIQSVFTRD LASIARLRIA KGGVNDNFQG VLQNVRFVFG TTPEDILRNK GCSSSTSVLL
     TLDNNVVNGS SPAIRTNYIG HKTKDLQAIC GISCDELSSM VLELRGLRTI VTTLQDSIRK
     VTEENKELAN ELRRPPLCYH NGVQYRNNEE WTVDSCTECH CQNSVTICKK VSCPIMPCSN
     ATVPDGECCP RCWPSDSADD GWSPWSEWTS CSTSCGNGIQ QRGRSCDSLN NRCEGSSVQT
     RTCHIQECDK RFKQDGGWSH WSPWSSCSVT CGDGVITRIR LCNSPSPQMN GKPCEGEARE
     TKACKKDACP INGGWGPWSP WDICSVTCGG GVQKRSRLCN NPTPQFGGKD CVGDVTENQI
     CNKQDCPIDG CLSNPCFAGV KCTSYPDGSW KCGACPPGYS GNGIQCTDVD ECKEVPDACF
     NHNGEHRCEN TDPGYNCLPC PPRFTGSQPF GQGVEHATAN KQVCKPRNPC TDGTHDCNKN
     AKCNYLGHYS DPMYRCECKP GYAGNGIICG EDTDLDGWPN ENLVCVANAT YHCKKDNCPN
     LPNSGQEDYD KDGIGDACDD DDDNDKIPDD RDNCPFHYNP AQYDYDRDDV GDRCDNCPYN
     HNPDQADTDN NGEGDACAAD IDGDGILNER DNCQYVYNVD QRDTDMDGVG DQCDNCPLEH
     NPDQLDSDSD RIGDTCDNNQ DIDEDGHQNN LDNCPYVPNA NQADHDKDGK GDACDHDDDN
     DGIPDDKDNC RLVPNPDQKD SDGDGRGDAC KDDFDHDSVP DIDDICPENV DISETDFRRF
     QMIPLDPKGT SQNDPNWVVR HQGKELVQTV NCDPGLAVGY DEFNAVDFSG TFFINTERDD
     DYAGFVFGYQ SSSRFYVVMW KQVTQSYWDT NPTRAQGYSG LSVKVVNSTT GPGEHLRNAL
     WHTGNTPGQV RTLWHDPRHI GWKDFTAYRW RLSHRPKTGF IRVVMYEGKK IMADSGPIYD
     KTYAGGRLGL FVFSQEMVFF SDLKYECRDP
//
